11:15 - 12:03
Prec-O2
Preclinical studies | Oral presentations 2
Chair/s:
Christiane Querfeld, Antonio Cozzio, Youn H Kim
11:15 - 11:27
Prec-O2-01
ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells
Oral presentation
Florent Amatore
(Centre de recherche en Cancérologie de Marseille, INSERM U1068, CNRS U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France | Department of Dermatology and Skin Cancers, Hôpital de la Timone, Aix-Marseille Université, Marseille, France | Department of Dermatology, Aix Marseille University, APHM, Hôpital Nord, Marseille, France)
 
11:27 - 11:39
Prec-O2-02
Anti-tumor effect of anti-apoptosis clone 11 protein-derived peptides on Sézary syndrome malignant CD4+ T lymphocytes
Oral presentation
Jean-Luc Poyet
(INSERM UMRS976, Institut de Recherche Saint Louis, Hôpital Saint Louis, Paris, France | Université de Paris, Paris, France)
 
11:39 - 11:51
Prec-O2-03
PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?
Oral presentation
Nicolas Ortonne
(Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France | Pathology department, APHP, Henri Mondor hospital, Paris, France)
 
11:51 - 12:03
Prec-O2-04
Functional remodeling of macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma
Oral presentation
Christiane Querfeld
(City of Hope, Division of Dermatology, Duarte, CA, United States | City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA, United States | City of Hope, Department of Pathology, Duarte, CA, United States | Beckman Research Institute, Duarte, CA, United States)